Nabriva Therapeutics plc saw its stock get a major boost on Monday morning after the company announced top-line results from their trial of a pneumonia drug.
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
Soleno Therapeutics presented new efficacy data from the pilot clinical trial of Diazoxide Choline Controlled-Release Tablet treating Prader-Willi syndrome at the International Meeting of Pediatric Endocrinology.
Soleno Therapeutics announced the issuance of a new US patent from the related to the use of pharmaceutical formulations of diazoxide and its salts.
By Shelly Kumar
CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) today released its financial results for the three and nine months ended July 31, 2017.
Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.
Opexa Therapeutics announced the recommendation it received for its shareholders from two advisory firms on matters related to their next meeting.
By Jocelyn Aspa
Glance Technologies (CSE:GET.CN) has announced that its partially-owned subsidiary, Cannapay Financial, has entered into an agreement to acquire the rights to a package of holistic Ayurveda formulas intended to treat a number of ailments.
As quoted in the press release:
Cannapay has agreed to purchase all of the intellectual property pertaining to
Voyager Therapeutics announced positive results from their ongoing Phase 1b trial of VY-AADC01 in advanced Parkinson’s disease.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
The Investing News reported took a closer look at some of the big cannabis news of the week and published an interview with the president of Cannabis Wheaton.
Dimension Therapeutics announced the start of patient dosing for their Phase 1/2 clinical trial to evaluate DTX301 for the treatment of patients with Ornithine Transcarbamylase deficiency.
VistaGen Therapeutics announced the pricing of an underwritten public offering of 1,371,430 shares of its common stock.